Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. Provides Strategic Update
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.